Tumor-Associated Antigen Expressing Listeria monocytogenes Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases-Reference-Cited by-同舟云学术

Tumor-Associated Antigen Expressing Listeria monocytogenes Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases

Published:2011-10-07 Issue:S3 Volume:19 Page:597-607
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Olino Kelly,Wada Satoshi,Edil Barish H.,Pan Xiaoyu,Meckel Kristen,Weber Walter,Slansky Jill,Tamada Koji,Lauer Peter,Brockstedt Dirk,Pardoll Drew,Schulick Richard,Yoshimura Kiyoshi

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://www.springerlink.com/index/pdf/10.1245/s10434-011-2037-0

Reference37 articles.

1. Hueman MT, Dehqanzada ZA, Novak TE, et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res. 2005;11:7470–9.

2. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145–56.

3. Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006;24:293–303.

4. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008;14:797–803.

5. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54:254–64.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy;Microsystems & Nanoengineering;2024-08-20

2. Exploiting bacteria for cancer immunotherapy;Nature Reviews Clinical Oncology;2024-06-05

3. Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future;Cell Communication and Signaling;2024-04-24

4. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines;Seminars in Cancer Biology;2023-01

5. Bacteria-based nanodrug for anticancer therapy;Pharmacological Research;2022-08